anastrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   123 Trials   123 Trials   2738 News 


«12345678910111213...4142»
  • ||||||||||  anastrozole / Generic mfg.
    Intermammary ulcer as the presenting finding of a rare mimicker of breast carcinoma (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_3121;    
    Considering the absence of pathological findings on the PET scan, besides those in relation to the intermammary ulcer, the diagnosis of a primary cutaneous adenocarcinoma could be made. Adnexal adenocarcinoma NOS is a rare malignant cutaneous adnexal tumor which presents with ductal differentiation but that has no other specific features to allow further classification.
  • ||||||||||  anastrozole / Generic mfg.
    A rare case of lichenoid drug eruption induced by an aromatase inhibitor anastrozole (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_1932;    
    In cases of disseminated and life-threatening reactions, it is mandatory to stop or, if possible, replace the incriminating drug. In the case of our patient, we decided to treat skin changes symptomatically, without discontinuing a potentially life-saving medication.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial primary completion date:  GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients (clinicaltrials.gov) -  Aug 5, 2024   
    P=N/A,  N=90, Recruiting, 
    In the case of our patient, we decided to treat skin changes symptomatically, without discontinuing a potentially life-saving medication. Trial primary completion date: Mar 2024 --> Jul 2024
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Trial completion date, Trial primary completion date:  Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast (clinicaltrials.gov) -  Aug 1, 2024   
    P1/2,  N=44, Active, not recruiting, 
    Trial completion date: Jul 2024 --> Dec 2025 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
  • ||||||||||  anastrozole / Generic mfg.
    BREAST CANCER AND LUNG NODULES OF UNCLEAR ETIOLOGY (Convention Center 253 C) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_4916;    
    She is maintained on anastrozole...- Pulmonary Langerhans Cell Histiocytosis is a rare disorder that should be considered on the differential with anyone smoking and nodules with cystic changes on CT scans. - Special staining for histiocytes was not done on the first biopsy, probably because Pulmonary Langerhans Cell Histiocytosis was not on the differential.
  • ||||||||||  bleomycin / Generic mfg., anastrozole / Generic mfg.
    MIGRATING FIBROIDS: A RARE CAUSE OF A SECONDARY SPONTANEOUS PNEUMOTHORAX (Convention Center Exhibit Hall: Rapid Fire Area 3B) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_1760;    
    Pulmonary BMLs are a rare cause of pulmonary nodules that have been reported to cause spontaneous pneumothoraces. Treatment options include surgical resection and/or hormonal suppression.
  • ||||||||||  anastrozole / Generic mfg.
    SUSPECTED ANASTROZOLE-INDUCED ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS (Convention Center Exhibit Hall: Poster Area 3) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_1682;    
    Her medical history included pulmonary embolism treated with Apixaban and breast cancer status post-mastectomy, currently on anastrozole. AAV, secondary to anastrozole, should be considered a potential diagnosis in any patient with cutaneous, renal, or pulmonary manifestations.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    RARE CASE OF THERAPY-RELATED ACUTE MYELOID LEUKEMIA FROM BREAST CARCINOMA MANAGEMENT WITH PALBOCICLIB (Convention Center Exhibit Hall: Poster Area 3) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_1591;    
    Arimidex was also started but was eventually discontinued due to worsening lung nodules on PET/CT...She was started on Venetoclax and Azacitidine, her pancytopenia improved, however, has overall poor prognosis...Gemcitabine's anti-AML activity and short-term exposure for other treatments make them unlikely to trigger t-AML. This report encourages analysis of long-term genotoxic side-effects of Palbociclib in breast cancer management and bone marrow biopsy is crucial when prolonged pancytopenia exists post treatment.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score (clinicaltrials.gov) -  Jul 28, 2024   
    P2,  N=50, Recruiting, 
    This report encourages analysis of long-term genotoxic side-effects of Palbociclib in breast cancer management and bone marrow biopsy is crucial when prolonged pancytopenia exists post treatment. Trial completion date: Jan 2030 --> Jul 2031 | Trial primary completion date: Jul 2025 --> Jan 2026
  • ||||||||||  Enrollment open:  Pre-Operative Window of ET to Inform RT Decisions (POWER II) (clinicaltrials.gov) -  Jul 23, 2024   
    P3,  N=284, Recruiting, 
    Trial completion date: Jan 2030 --> Jul 2031 | Trial primary completion date: Jul 2025 --> Jan 2026 Not yet recruiting --> Recruiting
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) -  Jul 17, 2024   
    P2,  N=19, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed
  • ||||||||||  anastrozole / Generic mfg., tamoxifen / Generic mfg.
    Journal:  Development of a Web-Based Interactive Tool for Visualizing Breast Cancer Clinical Trial Tolerability Data. (Pubmed Central) -  Jul 16, 2024   
    We have created an interactive web application and tool for clinicians and researchers to explore and visualize clinical trial tolerability data. This adaptable tool can be extended for other clinical trial data visualization and incorporated into future patient-clinician interactions regarding treatment decisions.
  • ||||||||||  anastrozole / Generic mfg., fulvestrant / Generic mfg.
    Journal:  A Positive Feedback Loop Exists between Estradiol and IL-6 and Contributes to Dermal Fibrosis. (Pubmed Central) -  Jul 13, 2024   
    Finally, dcSSc dermal fibroblasts treated with the estrogen receptor inhibitor fulvestrant also generated less FN, Col IIIA1, and Col VA1. Our data show that IL-6 exerts its pro-fibrotic influence in human skin in part through E2 and establish a positive feedback loop between E2 and IL-6.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Trial completion date, Trial primary completion date:  Roll-over Study to Allow Continued Access to Ribociclib (clinicaltrials.gov) -  Jun 12, 2024   
    P4,  N=137, Recruiting, 
    Unknown status --> Completed Trial completion date: Sep 2029 --> Mar 2030 | Trial primary completion date: Aug 2029 --> Feb 2030
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Trial completion date, Trial primary completion date:  Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer (clinicaltrials.gov) -  Jun 7, 2024   
    P2,  N=32, Recruiting, 
    Use of abemaciclib for treatment of high-risk EBC was described, which could help inform patient selection and treatment patterns. Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2025
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Trial primary completion date, Metastases:  Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer (clinicaltrials.gov) -  Jun 6, 2024   
    P2,  N=20, Recruiting, 
    Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2025 Trial primary completion date: Dec 2023 --> Dec 2025
  • ||||||||||  Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
    Enrollment closed, Trial completion date, Trial primary completion date:  Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) -  Jun 3, 2024   
    P3,  N=271, Active, not recruiting, 
    Trial primary completion date: Dec 2023 --> Dec 2025 Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Jan 2025 | Trial primary completion date: Sep 2024 --> Jan 2025
  • ||||||||||  anastrozole / Generic mfg., clomifene citrate / Generic mfg.
    Observational data, Journal:  Eligibility for the medical therapy among men with non-obstructive azoospermia-Findings from a multi-centric cross-sectional study. (Pubmed Central) -  May 28, 2024   
    Findings from this multicentric cross-sectional study reveal that about 30% of men with NOA were eligible for hormonal treatment with CC and/or hCG while 37% were found to be potential candidates for AIs, and 17% for both therapies. Therefore, these findings show that a only a small subset of NOA patients can benefit from medical therapy prior to considering any SR procedures.
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
    Journal:  Cytochrome P450 enzymes as drug targets in human disease. (Pubmed Central) -  May 16, 2024   
    Significance Statement The selective inhibition of certain P450s that have major physiological functions has been shown to be very efficacious in certain human diseases. In several cases the search for better drugs continues.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  Endocrine Response in Women With Invasive Lobular Breast Cancer (clinicaltrials.gov) -  May 13, 2024   
    P2,  N=201, Active, not recruiting, 
    Trial completion date: Mar 2024 --> Oct 2032 Trial completion date: Mar 2025 --> Jul 2024 | Trial primary completion date: Mar 2024 --> Jul 2024
  • ||||||||||  anastrozole / Generic mfg.
    Preclinical, Journal:  Testosterone Reduces Myelin Abnormalities in the Wobbler Mouse Model of Amyotrophic Lateral Sclerosis. (Pubmed Central) -  Apr 27, 2024   
    Since male WRs display low testosterone (T) levels in the nervous system, we investigated if T modified myelin-relative parameters in WRs in the absence or presence of the aromatase inhibitor, anastrozole (A)...A reduction of GS+ cells and GLT-1 immunoreactivity was observed in WRs and WR + T + A vs. controls and WR + T. Clinically, WR + T but not WR + T + A showed enhanced muscle mass, grip strength and reduced paw abnormalities. Therefore, T effects involve myelin protection, a finding of potential clinical translation.